Stan Smith

Director Stan Smith purchased 75,000 MAIA shares at $1.34; adds to strong timing track record at this ticker while company unprofitable at $-6.4M net income.

Stan Smith, a director, acquired 75,000 shares of MAIA at $1.34 on 2026-06-01, increasing his holdings by 5.2% to 1,519,178 shares. His prior 5 trades at MAIA show a 5 of 5 pattern of well-timed purchases, with 90-day returns ranging from +19.3% to +133.0%, and his cross-ticker open-market history spans 16 buys with an 87.50% 90-day win rate and average 90d return of +47.3%. However, the current context is pressured: MAIA trades at $1.30 today, -59.2% from its 52-week high of $3.19 and down 13.9% over the past 90 days, while the company reported negative net income of $-6.4M in its most recent fiscal year. A cluster pattern is also present—2 other insiders bought within the past 14 days—suggesting coordinated accumulation at these depressed levels. The historical timing success does not guarantee future returns, especially in an unprofitable company with significant recent price deterioration.

Director Smith Stan bought 2,700 shares of MAIA at $3.69 on 2022-09-19; stock now $1.57 (-57.5% since trade).

Director Smith Stan purchased 2,700 shares at $3.69 on 2022-09-19, bringing his holdings to 1,444,178 shares. The company was unprofitable with net income of $-8,903,189.00 over its most recent full fiscal year. The current stock price of $1.57 represents a significant decline from the transaction price, and the current price remains -36.7% from the 52-week high of $2.48. His cross-ticker track record shows 18 prior buys with a 72.73% 90-day win rate and average 90d return of +23.6%, though at MAIA specifically, 0 of 0 prior buys were well-timed at the 90-day mark. The recent trading pattern at MAIA shows multiple buys in late 2025 with positive near-term returns, but the 2022-09-19 purchase has proven to be poorly timed in context of the stock's subsequent long-term decline.

Director Smith Stan purchases 57,189 shares of MAIA at $1.22; stock -45.2% from 52-week high; unprofitable company with cluster buying pattern

Smith Stan purchased 57,189 shares at $1.22 on 2025-12-22, bringing his total holdings to 1,421,478 shares. MAIA Biotechnology is currently trading at $1.36, which is -45.2% from its 52-week high of $2.48, though the stock has recovered +49.2% over the past 30 days. The company reported a net loss of $-8.9M over its most recent full fiscal year, operating as an unprofitable business. Notably, this purchase is part of a cluster pattern with 2 other insiders also buying within the past 14 days, and Smith Stan's prior MAIA purchases at this ticker all remain unmeasured (within their first 30 days), preventing assessment of execution quality at this specific ticker. His broader cross-ticker track record shows 17 prior open-market buys with a 70.00% 90-day win rate and +25.7% average 90-day return, but this historical performance across other securities does not directly predict success in an unprofitable biotech with recent steep losses.

Director Smith Stan bought 13.7K shares at $1.20 blended average; MAIA unprofitable with -$8.9M net income; 2 other insiders also bought within 14 days.

On 2025-12-05, Director Stan Smith executed 3 separate purchases totaling 13,740 shares for $16,440.83 at a blended average price of $1.20. This accumulation occurs at a stock price 45.6% below the 52-week high and represents significant new conviction, occurring just days after his prior buys on 2025-11-26, 2025-11-25, and 2025-11-24. The cluster pattern—with 2 other insiders also buying within the past 14 days—suggests coordinated leadership conviction during a period of weakness. However, this conviction must be weighed against fundamentals: MAIA is deeply unprofitable, posting a net loss of $8,903,189.00 over its most recent full fiscal year and carries a modest $49,993,614.45 market cap, indicating investors are pricing in material distress or turnaround risk. Smith's cross-ticker buy history shows strong timing (70.00% 90-day win rate, average 90d return +25.7%), though at this ticker specifically, his limited measurable outcomes are mixed.

Director Stan Smith bought 15,000 shares of MAIA at $1.04; stock down -51.6% from 52-week high amid cluster buy pattern.

Director Stan Smith purchased 15,000 shares at $1.04 on 2025-11-26, raising his holdings to 1.36M shares, as MAIA trades at $1.20—down 51.6% from its 52-week high of $2.48 and off 20.0% over the past 90 days. This buy occurs within a cluster of 2 other insiders purchasing over the past 14 days, suggesting coordinated accumulation at depressed levels. Smith's cross-ticker track record shows strong timing discipline: 13 prior buys averaging +17.8% return in 30 days and +25.7% in 90 days, with a 70% win rate—though his 5 prior MAIA-specific trades are mixed, with 2 of 2 completed 90-day outcomes positive but the most recent three trades outcome-unmeasurable or still in loss territory (-4.6% at 30 days for the October purchase). The company remains unprofitable with net income of $-8.9M and a $44.4M market cap, adding material risk to the signal.

Director Stan Smith bought 25,000 shares at $0.98–$0.99 over 2 days; stock down 29.3% in 30 days, but insider shows 70% win rate and cluster buying pattern.

Stan Smith, Director of MAIA, executed 2 separate purchases totaling 25,000 shares for $24,600.00 at a blended average price of $0.98, increasing his holdings from 1.32M to 1.35M shares. The current price of $1.06 is 57.3% below the 52-week high and down 29.3% over the past 30 days—a meaningful decline that preceded this buy window. Smith's cross-ticker track record shows 12 prior buys with a 70% win rate and positive average 90-day returns of 25.7%; his prior buys at MAIA specifically were well-timed at the 90-day mark in 3 of 3 measurable cases. A cluster pattern is present: 2 other insiders also bought within the past 14 days. However, MAIA remains unprofitable with negative net income of $-8.9M and a market cap of $39.3M, warranting investor scrutiny of whether price decline reflects temporary volatility or deteriorating fundamentals.

Director Stan Smith bought 19,230 shares at $1.30 on 2025-10-01; 4 of 5 prior MAIA purchases showed positive 90d returns; current price $1.80.

Stan Smith, a director at MAIA Biotechnology, purchased 19,230 shares at $1.30 on 2025-10-01, increasing his holdings from 1,305,059 to 1,324,289 shares. This represents his sixth open-market purchase of MAIA stock within the past year. Notably, 4 of his 5 prior MAIA trades demonstrated positive 90-day returns following purchase, with post-trade price appreciation ranging from +1.3% to +23.3%, suggesting a pattern of favorable timing on this ticker. His cross-ticker buy track record across 10 prior transactions shows an average 90-day return of +25.7% with a 70% win rate, though the company itself is unprofitable with a most recent full-year net income of $-5,346,963.00. The stock has recovered +20.0% over the past 30 days but remains -45.8% below its 52-week high of $3.32, placing this purchase near a relative trough in recent valuation.

Director Stan Smith purchased 33,333 shares of MAIA at $1.50, adding to 1.31M-share position; stock down -61.8% from 52-week high amid $-4.5M net loss.

Stan Smith, a Director at MAIA Biotechnology, purchased 33,333 shares at $1.50 on 2025-06-03, expanding his holdings from 1,271,726 to 1,305,059 shares. This is his sixth transaction at MAIA within eight months, demonstrating sustained open-market buying activity at a deeply depressed valuation: the stock trades at $1.95, down -61.8% from its 52-week high of $5.10, and the company reported a $-4.5M net loss over its most recent full fiscal year. Among his prior five purchases at MAIA, two of four measurable outcomes showed positive 90-day returns (+19.3% and +14.0%), suggesting occasional timing success at this ticker. However, the current price of $1.95 has declined -5.3% over the past 30 days and remains well below both the transaction price and the peak, indicating the position has deteriorated since execution. The pattern reflects sustained accumulation into an unprofitable small-cap biotech in steep decline, a dynamic that merits scrutiny of the underlying business rationale.

Director Stan Smith buys 66,666 shares of MAIA at $1.50; holdings rise to 1,271,726 shares (+5.5%). Stock at $1.92, -62.4% from 52-week high.

Director Stan Smith purchased 66,666 shares at $1.50 on 2025-05-08, increasing his holdings to 1,271,726 shares and bringing his position up 5.5% from pre-transaction levels. The company is unprofitable with a net income of $-4,517,259.00 over its most recent full fiscal year, and the stock trades at $1.92, down 62.4% from its 52-week high of $5.10. Among Smith's prior five trades at MAIA, his timing has been mixed: one purchase on 2024-04-25 resulted in a strong 90-day return of +73.9%, but another on 2024-11-01 declined -25.9% over the same period, and only 1 of 3 prior buys with measurable 90-day outcomes reached positive returns, indicating a 33% well-timed rate at this ticker. The stock has recovered +28.0% over the past 30 days, but context of the company's ongoing losses and the insider's historically inconsistent timing at this specific ticker suggests caution in interpreting this purchase as a strong conviction signal.

MAIA director Smith Stan bought 25,000 shares at $1.50 on 2025-03-03, continuing accumulation pattern; stock -67.2% from 52-week high.

Director Smith Stan purchased 25,000 shares at $1.50, adding to holdings that now total 1,205,060 shares, extending a documented pattern of acquisitions at this ticker. The buy occurred while MAIA stock trades -67.2% from its 52-week high of $5.10, and follows a prior buy just 8 days earlier on 2025-02-24, suggesting sustained accumulation. Of his 5 prior open-market transactions at MAIA, 2 of the 3 completed 90-day windows showed positive returns (+73.9% and +218.0%), though the most recent measurable outcome (2024-11-01 entry) resulted in a -25.9% 90-day loss. The company remains unprofitable with a -$2.7M net income over the most recent full fiscal year, and the current $1.67 price represents an -11.6% decline over the past 30 days, raising questions about the basis for continued accumulation at a depressed valuation amid operating losses.